Related Experiment Videos
Metered dose inhaler therapy for asthma, bronchitis, and emphysema
1Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Abstract:
This review addresses the use of the metered dose inhaler (MDI) to administer aerosol therapy in the treatment of asthma, bronchitis, and emphysema. Studies have shown that physicians' prescribing patterns for use of the inhaler have been inconsistent with optimal therapy. Furthermore, the medical literature suggests that the metered dose inhaler should replace the jet nebulizer in hospital and outpatient settings as a more efficient and cost-effective treatment method. All classes of aerosol drugs are now available for administration by the MDI. Reports suggest that patients whose conditions do not respond to treatment administered by the MDI may improve following instruction in the proper method of using the inhaler or by increasing the recommended dosage of medication for those receiving beta-adrenergic, anticholinergic, and glucocorticoid drugs. A consensus now recommends that aerosol glucocorticoids be considered the primary method of therapy for asthma; however, the effectiveness of glucocorticoids in the treatment of bronchitis and emphysema has not been determined. Although available data do not prove that drugs used in the treatment of asthma increase mortality, further study is recommended in view of the potential toxicity of these drugs.
Insights
Metered dose inhalers (MDIs) offer efficient aerosol therapy for respiratory conditions like asthma. Proper MDI technique and dosage adjustments can improve patient outcomes, making them a preferred alternative to nebulizers.
Area of Science:
- Pulmonology
- Pharmacology
- Respiratory Medicine
Background:
- Metered dose inhalers (MDIs) are crucial for aerosol therapy in asthma, bronchitis, and emphysema.
- Physician prescribing patterns often deviate from optimal MDI therapy guidelines.
- MDIs are increasingly recognized as more efficient and cost-effective than jet nebulizers in healthcare settings.
Purpose of the Study:
- To review the current use of MDIs in aerosol therapy for obstructive airway diseases.
- To evaluate the efficacy and cost-effectiveness of MDIs compared to alternative delivery methods.
- To highlight optimal prescribing practices and patient-specific treatment adjustments for MDI use.
Main Methods:
- Literature review of studies on MDI use in asthma, bronchitis, and emphysema.
- Analysis of prescribing patterns and treatment outcomes associated with MDI therapy.
- Evaluation of drug classes available for MDI administration and their effectiveness.
Main Results:
- MDIs are suitable for all classes of aerosolized drugs.
- Improved patient outcomes are associated with proper MDI technique and adjusted dosages.
- Aerosol glucocorticoids are recommended as first-line therapy for asthma, but their role in bronchitis and emphysema requires further investigation.
- While MDI drugs for asthma haven't been proven to increase mortality, potential toxicity warrants further research.
Conclusions:
- MDIs represent an efficient and cost-effective method for aerosol therapy, potentially replacing jet nebulizers.
- Optimizing MDI technique and medication dosage can enhance treatment effectiveness for patients.
- Aerosol glucocorticoids are a cornerstone of asthma management, with ongoing research into their broader applications and safety profiles.